8-K: Gilead Sciences Reports Solid Q2 2024 Results Driven by HIV and Oncology Growth

Gilead Sciences announced a 5% increase in total revenue to $7.0 billion for the second quarter of 2024, driven by strong performance in HIV, Liver Disease, and Oncology.

Summary

• Gilead Sciences reported a 5% increase in total revenue to $7.0 billion for the second quarter of 2024, compared to the same period in 2023.
• Product sales, excluding Veklury, grew by 6% year-over-year to $6.7 billion.
• Biktarvy sales increased by 8% year-over-year to $3.2 billion, while oncology sales rose by 15% to $841 million.
• Diluted earnings per share (EPS) was $1.29, up from $0.83 in the prior year, and non-GAAP diluted EPS was $2.01, compared to $1.34 in 2023.
• The company's cash, cash equivalents, and marketable debt securities decreased to $2.8 billion as of June 30, 2024, primarily due to the acquisition of CymaBay Therapeutics and repayment of senior notes.
• Gilead generated $1.3 billion in operating cash flow during the quarter, net of a $1.2 billion transition tax payment.
• The company paid dividends of $972 million and repurchased $100 million of common stock in the second quarter.
• Full-year 2024 product sales guidance remains unchanged at $27.1 to $27.5 billion, while non-GAAP diluted EPS guidance was increased to $3.60 to $3.90.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, particularly in HIV and oncology, and the increase in non-GAAP EPS guidance. However, the negative results for Trodelvy in certain trials and the decrease in cash position temper the overall positive outlook.

Positives

• Gilead experienced strong growth in its base business, driven by HIV, Oncology, and Liver Disease therapies.
• Biktarvy sales showed significant growth, indicating continued market demand.
• The oncology portfolio demonstrated strong growth, particularly in cell therapy and Trodelvy sales.
• The company achieved a significant increase in diluted EPS and non-GAAP diluted EPS compared to the same period last year.
• The Phase 3 PURPOSE 1 trial showed 100% efficacy for lenacapavir in HIV prevention for cisgender women.
• The company generated $1.3 billion in operating cash flow during the quarter.
• Gilead increased its full-year non-GAAP diluted EPS guidance.

Negatives

• Veklury sales decreased by 16% due to lower COVID-19 related hospitalizations.
• Descovy sales decreased by 6% due to lower average realized price.
• The company's cash position decreased significantly due to the acquisition of CymaBay Therapeutics and repayment of senior notes.
• Trodelvy did not meet the primary endpoint of improvement in overall survival in the TROPiCS-04 study for urothelial cancer.
• The EVOKE-01 study evaluating Trodelvy in lung cancer did not meet its primary endpoint of overall survival.
• There was a higher number of deaths due to adverse events with Trodelvy in the TROPiCS-04 study.

Risks

• The company faces risks related to the uncertainty of Veklury revenues and its impact on full-year financial results.
• There are risks associated with the company's ability to progress clinical trials and obtain regulatory approvals for its product candidates.
• Gilead faces potential disruptions to its manufacturing and supply chain.
• Pricing and reimbursement pressures from government agencies and other third parties could impact revenue.
• Market share and price erosion caused by generic versions of Gilead products pose a risk.
• Physicians and patients may not see advantages of Gilead's products over other therapies.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Gilead expects full-year 2024 product sales to be between $27.1 and $27.5 billion, and non-GAAP diluted EPS to be between $3.60 and $3.90. The company anticipates additional clinical readouts and a potential launch of seladelpar in the United States.

Management Comments

• Daniel O'Day, Gilead's Chairman and Chief Executive Officer, stated that Gilead had another strong quarter with 6% year-over-year growth in the base business.
• He highlighted the interim data from the Phase 3 PURPOSE 1 trial showing 100% efficacy for lenacapavir in HIV prevention for cisgender women.

Industry Context

Gilead's results reflect the ongoing demand for HIV treatments and the growing importance of oncology therapies in the pharmaceutical industry. The company's focus on innovative medicines and strategic acquisitions positions it to compete effectively in these key therapeutic areas. The positive results for lenacapavir in HIV prevention could significantly impact the market for pre-exposure prophylaxis (PrEP).

Comparison to Industry Standards

• Gilead's 6% growth in product sales excluding Veklury is a solid performance compared to other large-cap biopharmaceutical companies, many of which are experiencing slower growth due to patent expirations and increased competition.
• The 8% growth in Biktarvy sales is particularly strong, indicating a continued preference for this treatment in the HIV market, and is likely outperforming competitors in the same space.
• The 15% growth in oncology sales is also notable, as many companies are investing heavily in this area, and Gilead's performance suggests a strong position in the market.
• The 100% efficacy of lenacapavir in the PURPOSE 1 trial is a significant achievement and could set a new standard for HIV prevention, potentially surpassing the efficacy of current PrEP options like Truvada and Descovy.
• However, the failure of Trodelvy to meet primary endpoints in the TROPiCS-04 and EVOKE-01 trials is a setback, and highlights the challenges in oncology drug development, where many trials fail to meet their goals. This is not uncommon in the industry, but it does impact the potential of Trodelvy in these specific indications.
• The decrease in Veklury sales is consistent with the decline in COVID-19 hospitalizations, which is a trend seen across the industry for COVID-19 related treatments.

Management Changes

Legal Proceedings

• Gilead reached a settlement agreement in principle in the federal TDF litigation, with a one-time payment of up to $40 million.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and earnings, as well as the increased non-GAAP EPS guidance.
• Employees will be impacted by the company's performance and future growth prospects.
• Patients will benefit from the development of new and innovative medicines.
• Customers will be impacted by the availability and pricing of Gilead's products.
• Suppliers and creditors will be impacted by the company's financial performance and stability.

Next Steps

• Gilead will continue to advance its clinical programs and seek regulatory approvals for its product candidates.
• The company will focus on the potential launch of seladelpar for primary biliary cholangitis in the United States.
• Gilead will continue to monitor the performance of its key products, including Biktarvy, Trodelvy, and Veklury.
• The company will continue to evaluate potential acquisitions and collaborations to expand its pipeline and market presence.

Key Dates

Keywords

Gilead Sciences, HIV, Oncology, Biktarvy, Trodelvy, Veklury, Lenacapavir, Earnings, Financial Results, Pharmaceuticals